West Pharmaceutical Services (WST) Stock Forecast & Price Target

West Pharmaceutical Services
Bull Case

Here are some ways that investors could benefit from investing in West Pharmaceutical Services, Inc.:

• West Pharmaceutical Services, Inc. recently reported strong second-quarter results on July 23, 2026, with earnings per share of $2.37, which beat the analyst consensus estimate of $2.08 by $0.29, demonstrating the company's ability to exceed market expectations and drive shareholder value through robust operational performance.
• The company has established a clear path for future growth driven by the multiyear Annex 1 regulatory opportunity, which represents a significant mix shift in the pharmaceutical packaging industry, with only a small fraction of the estimated $6 billion component opportunity converted so far, suggesting substantial long-term revenue potential as pharmaceutical companies upgrade their facilities.
• West Pharmaceutical Services, Inc. is currently trading at $363.52, a price that reflects strong institutional confidence, as evidenced by recent 13F filings showing that major institutional investors like Envestnet Asset Management Inc. and State Street Corp increased their positions in the stock during the second quarter, indicating that professional money managers view the company as a solid investment.
• The stock has demonstrated significant momentum, reaching a 52-week high of $386.00 in July 2026, and the company has set optimistic guidance for the third quarter of 2026, projecting earnings per share between $2.14 and $2.24, which is above the consensus estimate of $2.13, signaling continued strong financial health and growth trajectory.
• West Pharmaceutical Services, Inc. benefits from a favorable analyst consensus, with a "Moderate Buy" rating and an average price target of $382.00, which is higher than the current stock price, suggesting that analysts believe the stock has room to appreciate further as the company continues to execute on its strategic initiatives and deliver strong earnings.